Adenosine kinase is critical for neointima formation after vascular injury by inducing aberrant DNA hypermethylation
Adenosine kinase is critical for neointima formation after vascular injury by inducing aberrant DNA hypermethylation
复制标题
腺苷激酶通过诱导异常 DNA 高甲基化对血管损伤后新内膜形成至关重要
DOI:
10.1093/cvr/cvaa040
复制
发表时间:
2021-02-01
影响因子:
10.8
通讯作者:
Huo, Yuqing
中科院分区:
文献类型:
--
作者:
Wang, Yong;Xu, Yiming;Huo, Yuqing
Aims Adenosine receptors and extracellular adenosine have been demonstrated to modulate vascular smooth muscle cell (VSMC) proliferation and neointima formation. Adenosine kinase (ADK) is a major enzyme regulating intracellular adenosine levels but is function in VSMC remains unclear. Here, we investigated the role of ADK in vascular injury-induced smooth muscle proliferation and delineated the mechanisms underlying its action.Methods and results We found that ADK expression was higher in the neointima of injured vessels and in platelet-derived growth factor-treated VSMCs. Genetic and pharmacological inhibition of ADK was enough to attenuate arterial injury-induced neointima formation due to inhibition of VSMC proliferation. Mechanistically, using infinium methylation assays and bisutfite sequencing, we showed that ADK metabolized the intracellular adenosine and potentiated the transmethylation pathway, then induced the aberrant DNA hypermethylation. Pharmacological inhibition of aberrant DNA hypermethylation increased KLF4 expression and suppressed VSMC proliferation as well as the neointima formation. Importantly, in human femoral arteries, we observed increased ADK expression and DNA hypermethylation as well as decreased KLF4 expression in neointimat VSMCs of stenotic vessels suggesting that our findings in mice are relevant for human disease and may hold translational significance.Conclusion Our study unravels a novel mechanism by which ADK promotes VSMC proliferation via inducing aberrant DNA hypermethylation, thereby down-regulating KLF4 expression and promoting neointima formation. These findings advance the possibility of targeting ADK as an epigenetic modulator to combat vascular injury.[GRAPHICS].